Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.

about

Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.

Item

http://www.wikidata.org/entity/Q47349096

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Synergistic cytotoxicity of a ...... with the BH3 mimetic ABT-737.

@en

Synergistic cytotoxicity of a ...... with the BH3 mimetic ABT-737.

@nl

type

Item

label

Synergistic cytotoxicity of a ...... with the BH3 mimetic ABT-737.

@en

Synergistic cytotoxicity of a ...... with the BH3 mimetic ABT-737.

@nl

prefLabel

Synergistic cytotoxicity of a ...... with the BH3 mimetic ABT-737.

@en

Synergistic cytotoxicity of a ...... with the BH3 mimetic ABT-737.

@nl

P1476

Synergistic cytotoxicity of a ...... with the BH3 mimetic ABT-737.

@en

P2093

Irina Kuckuck

http://www.w3.org/2001/XMLSchema#string

Marta Michalska

http://www.w3.org/2001/XMLSchema#string

Susanne Schultze-Seemann

http://www.w3.org/2001/XMLSchema#string

Theresa Noll

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Pseudomonas Exotoxin A: optimized by evolution for effective killing

Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma

Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group.

Reprogramming cell death: BCL2 family inhibition in hematological malignancies.

The Bcl-2 family: roles in cell survival and oncogenesis.

Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.

Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells

P2888

s00262-017-2097-5

P304

413-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-017-2097-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philipp Wolf

P577

2017-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29188305

http://www.w3.org/2001/XMLSchema#string